Drug VX-770 Reduces Pulmonary Fibrosis in Mice
Researchers find that VX-770 restores lung function by stabilizing proteins within a mouse model of fibrosis.
Updated on Oct. 31, 2026 in Asthma
A recent study demonstrates that the drug VX-770 effectively reduces pulmonary fibrosis and collagen deposition in mice. By stabilizing the CFTR-PTEN protein complex, the treatment restores normal lung structure and function.
Why it matters
Acquired CFTR dysfunction in alveolar type 2 cells is a key contributor to the development of pulmonary fibrosis. This mechanism suggests a new pathway for therapeutic intervention in lung disease.
In a bleomycin-induced model, VX-770 successfully decreased collagen deposition and lowered the expression of senescence markers in AT2 cells. The treatment's efficacy relies on elevated PTEN levels to inhibit the PI3K/AKT signaling pathway.
The players
VX-770
This is a pharmacological agent currently being studied for its ability to stabilize protein complexes and inhibit specific signaling pathways associated with fibrosis.
The details
The drug works by stabilizing the CFTR-PTEN protein complex, which effectively blocks the profibrotic PI3K/AKT signaling pathway. Researchers observed that when CFTR was deleted in AT2 cells, the therapeutic benefits of the drug were significantly lessened.
Timeline
The research findings were published on October 31, 2026.
The Big Picture
This study advances the scientific understanding of the PI3K/AKT signaling pathway as a primary target for lung disease therapy. It challenges the notion that fibrosis-related lung damage is strictly irreversible by demonstrating structural restoration in preclinical models.
While these findings are limited to preclinical models, they open a potential new avenue for treatments aimed at reversing lung tissue scarring. Future human trials will be required to determine if this therapy could eventually impact treatment options for respiratory patients.
The takeaway
Targeting protein stabilization provides a promising strategy for inhibiting pathways that lead to lung fibrosis. Researchers are looking toward these mechanisms as a way to preserve lung health at the cellular level.
Further reading
For more information on the latest respiratory research, visit the Asthma section.
Source note: This article includes information reported by Nature.
